References
1. Pizzo PA, Poplack DG. Principles and Practices of Pediatric Oncology.
7th ed. Wolters Kluwer, 2016:1266p.
2. Lal BK. The Superior Vena Cava Syndrome: Clinical Characteristics and
Evolving Etiology. Yearbook of Vascular Surgery. 2008 Jan;2008:376.
3. Higdon ML, Benning F, Higdon JA. Treatment of Oncologic Emergencies.
Oncologic Emergencies. 2006;74(11):8.
4. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis,
leukostasis and leukapheresis: Practice management. Blood Reviews. 2012
May;26(3):117–22.
5. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann
M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can
decrease treatment burden and improve survival: treatment results of
2169 unselected pediatric and adolescent patients enrolled in the trial
ALL-BFM 95. Blood. 2008 May 1;111(9):4477–89.
6. Hoelzer D, Gökbuget N. T-Cell Lymphoblastic Lymphoma and T-Cell Acute
Lymphoblastic Leukemia: A Separate Entity? Clinical Lymphoma and
Myeloma. 2009 Sep;9:S214–21.
7. Freud E, Ben-Ari J, Schonfeld T, Blumenfeld A, Steinberg R, Dlugy E,
et al. Mediastinal Tumors in Children: A Single Institution Experience.
Clin Pediatr (Phila). 2002 May;41(4):219–23.
8. Haut C. Oncological Emergencies in the Pediatric Intensive Care Unit:
AACN Clinical Issues: Advanced Practice in Acute and Critical Care. 2005
Apr;16(2):232–45.
9. Morin S, Grateau A, Reuter D, de Kerviler E, de Margerie-Mellon C, de
Bazelaire C, et al. Management of superior vena cava syndrome in
critically ill cancer patients. Supportive Care in Cancer. 2018 Feb
1;26(2):521–8.
10. Tilak TVSVGK, Raina V, Kumar L, Sharma A, Sharma MC, Vishnubhatla S,
et al. Superior vena cava syndrome and poor performance status at
presentation affect survival in mediastinal T-lymphoblastic lymphoma—a
single institute experience from India. Annals of Hematology. 2013 Jul
1;92(7):917–23.
11. Bhaker P, Das A, Rajwanshi A, Gautam U, Trehan A, Bansal D, et al.
Precursor T-lymphoblastic lymphoma: Speedy diagnosis in FNA and effusion
cytology by morphology, immunochemistry, and flow cytometry. Cancer
Cytopathology. 2015 Sep 1;123(9):557–65.
12. Czader M, Ali SZ. Flow cytometry as an adjunct to cytomorphologic
analysis of serous effusions. Diagnostic Cytopathology. 2003 Aug
1;29(2):74–8.
13. Cesana C, Scarpati B, Brando B, Barba C, Ferri U, Scampini L, et al.
Flow Cytometric Examination of Non-Hematic Body Fluids in Hematologic
Malignancies: A Comparison with Cytology. Blood. 2007 Nov
16;110(11):4237–4237.
14. Cesana C, Klersy C, Scarpati B, Brando B, Faleri M, Bertani G, et
al. Flow cytometry and cytomorphology evaluation of hematologic
malignancy in cerebrospinal fluids: comparison with retrospective
clinical outcome. Ann Hematol. 2011 Jul;90(7):827–35.
15. Nossair F, Schoettler P, Starr J,et al. Pediatric superior vena cava
syndrome: An evidence based systematic review of the literature.Pediatr Blood Cancer .2018;e27225.
16. Ramzan M, Yadav SP, Sachdeva A. Treatment abandonment is a major
hurdle to improving survival in childhood cancer in the developing
world. Pediatric Blood & Cancer. 2013 Jan 1;60(1):159–60.
17. Yadav SP, Rastogi N, Kharya G, Misra R, Ramzan M, Katewa S, et al.
Barriers to Cure for Children with Cancer in India and Strategies to
Improve Outcomes: A Report by the Indian Pediatric Hematology Oncology
Group.2014 Apr 1;31(3):217–24.